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New antidepressants or more of the same?
Effective antidepressant drugs have been available for half a century since the ﬁ  rst 
monoamine oxidase inhibitor (MAOI), isoniazid, and the prototype tricyclic antidepres-
sant (TCA), imipramine, were introduced into therapy (Leonard and Spencer 1990). 
The use of MAOIs declined when reports appeared of hypertensive crises associated 
with ingestion of dietary tyramine, and the TCAs, despite their shortcomings in safety 
and tolerability, became the mainstays of treatment. A second generation of drugs of 
various classes was developed with diverse chemical structures and different mecha-
nisms of action (Pinder and Wieringa 1993), of which the most widely prescribed 
have been the selective serotonin reuptake inhibitors (SSRIs). Although modern drug 
discovery technologies like combinatorial chemistry and high-throughput screening 
have made less likely the identiﬁ  cation of truly novel agents (Pinder 2001), new agents 
and biological targets continue to be investigated (Bosker et al 2004). Psychological 
treatments, including cognitive and interpersonal therapies, also have their place in 
the acute and maintenance treatment of depression (DeRubels et al 2005).
Two of the new kids on the block have been reviewed in recent issues of Neuropsy-
chiatric Disease and Treatment. One is a new formulation of an old irreversible MAOI, 
selegiline, and is the ﬁ  rst transdermal antidepressant to be introduced (Lee and Chen 2007), 
while the second, agomelatine, has a novel mechanism of action in being a melatonin 
receptor agonist and a serotonergic (5-HT2c) antagonist (Kennedy and Eisfeld 2007). The 
selegiline transdermal system (STS) has already received US Food and Drug Administra-
tion (FDA)-approval, while agomelatine may be approved shortly by the European Agency 
for the Evaluation of Medicinal Products (EMEA). Do these newcomers represent major 
advances in therapy?
For US physicians, the use of MAOIs has long been restricted to phenelzine, 
tranylcypromine, and isocarboxazid, with most prescriptions being written for phen-
elzine. As the only MAOI available in the USA for the treatment of depression that 
does not require dietary restriction at clinically effective doses, STS is likely to ﬁ  nd a 
place in the antidepressant armamentarium particularly for the treatment of atypical 
depression, treatment-resistant patients, and those with accompanying anxiety disor-
ders (Lee and Chen 2007). Outside the USA, physicians have long had access to the 
reversible MAOI moclobemide which also lacks dietary restrictions. If STS comes to 
Europe or to other parts of the world, it is likely to be the novelty factor that prompts 
physicians to prescribe a transdermal agent or the demand from patients for a non-
oral therapy, rather than any perceived superiority to moclobemide. Oral selegiline 
is approved only as an adjunctive treatment in Parkinson’s disease; it enjoyed a brief 
vogue as a neuroprotective agent in monotherapy, but large clinical trials showed that 
it was more suitable as an add-on to dopamine agonists particularly levodopa.
Agomelatine is the more interesting newcomer from the mechanistic viewpoint. As 
a modulator of both the M1 and M2 types of melatonin receptor, it could play a role in 
regulating the suprachiasmatic nucleus circadian clock and thereby restore disruption 
of the sleep-wake cycle and circadian rhythms. Depression is characterized in part by 
altered patterns of sleep, and both sleep- and REM-sleep deprivation are effective as 
acute treatments. The antidepressant efﬁ  cacy and relative safety of agomelatine have 
been established in several large clinical trials while its sleep restorative properties, 520
Pinder
Neuropsychiatric Disease and Treatment 2007:3(5)
lack of sedation and minimal effects on sexual function make 
it suitable for general use (Kennedy and Eisfeld 2007). Its 
potential role in sleep disorders and jet lag have hardly been 
explored so far.
Neither of these drugs represents a breakthrough in 
the treatment of depression, but are the latest incremental 
advances in our ability to address the most common mental 
health problem of our age. We still need antidepressants 
that act faster to produce more response and remission; the 
gains of the last decades since the introduction of MAOIs 
and TCAs have been more in safety and tolerability than in 
efﬁ  cacy. Improvements in diagnosis and our emerging ability 
to characterize different forms of depression in biological 
terms may ultimately help to develop more targeted treat-
ments of greater efﬁ  cacy. 
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